Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | LDHA | P00338 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1423651 | 0.95 | HTR2A (0.44) | HTR2AHTR2CLDHA | |
| SCHEMBL28517075 | 0.93 | HTR2A (0.44) | HTR2AHTR2CLDHA | |
| Potassium Ion SCHEMBL5123542 | 0.82 | HTR2A (0.39) | HTR2AHTR2CPDK1PDK2LDHA | |
| SCHEMBL22518543 | 0.80 | HTR2A (0.40) | HTR2AHTR2CPDK1PDK2LDHA | |
| SCHEMBL24811454 | 0.78 | HDAC6 (0.38) | HTR2AHTR2CPDK1PDK2 | |
| SCHEMBL22831695 | 0.78 | PDCD1 (0.36) | TSHR | |
| SCHEMBL1008113 | 0.77 | CYP1A2 (0.48) | ALOX15TSHRHIF1A | |
| SCHEMBL20228734 | 0.77 | HTR2A (0.38) | HTR2AHTR2CPDK1PDK2LDHA | |
| SCHEMBL22275219 | 0.75 | ALDH1A1 (0.43) | HTR2AHTR2CLDHA | |
| SCHEMBL25485602 | 0.75 | HTR2A (0.44) | HTR2AHTR2CPDK1PDK2LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009634-A1 | Process for synthesizing beta-lactamase inhibitor intermediates | WYETH HOLDINGS CORPORATION (US) | 2008-01-10 | — | — | US | claimed |
| CN-1823074-A | Process for synthesizing beta-lactamase inhibitor intermediates | WYETH CORP (US) | 2006-08-23 | — | — | CN | claimed |
| EP-1626975-A2 | PROCESS FOR SYNTHESIZING ß-LACTAMASE INHIBITOR IN INTERMEDIATES | Wyeth Holdings Corporation (US) | 2006-02-22 | — | — | EP | claimed |
| WO-2004104006-A2 | PROCESS FOR SYNTHESIZING β-LACTAMASE INHIBITOR IN INTERMEDIATES | WYETH HOLDINGS CORPORATION (US) | 2004-12-02 | — | — | WO | claimed |
| US-20040242874-A1 | Process for synthesizing beta-lactamase inhibitor intermediates | WYETH HOLDINGS CORPORATION | 2004-12-02 | — | — | US | claimed |
| US-20260125346-A1 | Isoquinolinone Derivatives and 4H-Quinolizinone Derivatives and Pharmaceutical Compositions Thereof for the Treatment of Disease | BEONE MEDICINES I GMBH (CH) | 2026-05-07 | — | — | US | disclosed |
| EP-4709711-A1 | ISOQUINOLINONE DERIVATIVES AND 4H-QUINOLIZINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASE | Beone Medicines I GmbH (CH) | 2026-03-18 | — | — | EP | disclosed |
| EP-4688154-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | BIAL - Portela & Ca., S.A. (PT) | 2026-02-11 | — | — | EP | disclosed |
| EP-4688155-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | Bial-Portela & CA, S.A. (PT) | 2026-02-11 | — | — | EP | disclosed |
| US-12459951-B2 | Compounds that interact with RAS superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY THERAPEUTICS, LLC (US) | 2025-11-04 | — | — | US | disclosed |
| CN-120058672-A | Halogenated pyridylcarboxylic acid ester derivative and application thereof | 贵州医科大学 | 2025-05-30 | — | — | CN | disclosed |
| US-20250154134-A1 | COMPOUND AS FAK INHIBITOR AND USE THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2025-05-15 | — | — | US | disclosed |
| CN-1823069-A | Process for synthesizing beta-lactamase inhibitor intermediates | WYETH CORP (US) | 2006-08-23 | — | — | CN | disclosed |
| EP-1626972-A1 | PROCESS FOR SYNTHESIZING ß-LACTAMASE INHIBITOR INTERMEDIATES | Wyeth Holdings Corporation (US) | 2006-02-22 | — | — | EP | disclosed |
| EP-1626975-A2 | PROCESS FOR SYNTHESIZING ß-LACTAMASE INHIBITOR IN INTERMEDIATES | Wyeth Holdings Corporation (US) | 2006-02-22 | — | — | EP | disclosed |
| CN-1649883-A | Bicyclic 6-alkylidene-epimycotenes as lactamase inhibitors | WYETH CORP (US) | 2005-08-03 | — | — | CN | disclosed |
| WO-2004104006-A2 | PROCESS FOR SYNTHESIZING β-LACTAMASE INHIBITOR IN INTERMEDIATES | WYETH HOLDINGS CORPORATION (US) | 2004-12-02 | — | — | WO | disclosed |
| WO-2004104008-A1 | PROCESS FOR SYNTHESIZING β-LACTAMASE INHIBITOR INTERMEDIATES | WYETH HOLDINGS CORPORATION (US) | 2004-12-02 | — | — | WO | disclosed |
| US-20040242874-A1 | Process for synthesizing beta-lactamase inhibitor intermediates | WYETH HOLDINGS CORPORATION | 2004-12-02 | — | — | US | disclosed |
| US-20040229324-A1 | Production of bicyclic-heteroaryl-2-carboxylic acids by selective enzymatic hydrolysis of a mixture of positional esters | WYETH HOLDINGS CORPORATION | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009634-A1 | Process for synthesizing beta-lactamase inhibitor intermediates | COASY, DCXR, MGAM | HTR2A 3395/4885HTR2C 3603/4885PDK1 1267/4885 |
| US-20040229324-A1 | Production of bicyclic-heteroaryl-2-carboxylic acids by selective enzymatic hydrolysis of a mixture of positional esters | COASY, CES2, CES1 | HTR2A 3771/4885HTR2C 3650/4885PDK1 833/4885 |
| US-12459951-B2 | Compounds that interact with RAS superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | KRAS, HRAS, NRAS | HTR2A 4770/4885HTR2C 4822/4885PDK1 2943/4885 |
| US-20040242874-A1 | Process for synthesizing beta-lactamase inhibitor intermediates | COASY, DCXR, MGAM | HTR2A 3362/4885HTR2C 3537/4885PDK1 1224/4885 |
| US-20260125346-A1 | Isoquinolinone Derivatives and 4H-Quinolizinone Derivatives and Pharmaceutical Compositions Thereof for the Treatment of Disease | NR3C1, NR3C2, PIK3R4 | HTR2A 261/4885HTR2C 325/4885PDK1 544/4885 |
| US-20250154134-A1 | COMPOUND AS FAK INHIBITOR AND USE THEREOF | PTK2, PAK1, FYN | HTR2A 4185/4885HTR2C 3867/4885PDK1 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.